RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+15.08%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$810M
AUM Growth
+$146M
(+22%)
Cap. Flow
+$85.4M
Cap. Flow
% of AUM
10.54%
Top 10 Holdings %
Top 10 Hldgs %
36.98%
Holding
72
New
23
Increased
22
Reduced
9
Closed
15
Avg Time Held Equity + Options
0.2
years
Top 10 Avg Time Held Equity + Options
0.1
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.2
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$32.8M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$20.4M |
| 3 |
Incyte
INCY
|
+$19.5M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$18.9M |
| 5 |
AGN
Allergan Inc
AGN
|
+$18.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$38.7M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$28.8M |
| 3 |
STJ
St Jude Medical
STJ
|
+$25.8M |
| 4 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
+$23.3M |
| 5 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.06% |
| 2 | Miscellaneous | 12.08% |
| 3 | Consumer Staples | 1.18% |
| 4 | Technology | 0.55% |
| 5 | Communication Services | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
iShares US Healthcare Providers ETF
IHF
$1.41B
| $280K | 0.03% |
+15,000
| New | +$270K |
2013 Q4
0 quarters
|
|
52
Regeneron Pharmaceuticals
REGN
$80.1B
| $275K | 0.03% |
1,000
-79,400
| -99% | -$22.8M |
2013 Q2
2 quarters
|
|
53
Prothena Corp
PRTA
$430M
| $241K | 0.03% |
+9,100
| New | +$228K |
2013 Q4
0 quarters
|
|
|
DYAX
54
DELISTED
DYAX CORPORATION
DYAX
| $188K | 0.02% |
+25,000
| New | +$190K |
2013 Q4
0 quarters
|
|
55
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $166K | 0.02% |
+167
| New | +$173K |
2013 Q4
0 quarters
|
|
56
Merck
MRK
$364B
| $120K | 0.01% |
2,515
+524
| +26% | +$24K |
2013 Q3
1 quarter
|
|
57
Agios Pharmaceuticals
AGIO
$1.85B
| – | – |
-53,100
| Closed | -$1.49M | – |
|
|
58
Amgen
AMGN
$230B
| – | – |
-345,700
| Closed | -$38.7M | – |
|
59
Brookdale Senior Living
BKD
$2.41B
| – | – |
-757,800
| Closed | -$19.9M | – |
|
60
Nuwellis
NUWE
$1.68M
| – | – |
0
| – | -$5.45M |
2013 Q3
1 quarter
|
|
61
Pacific Biosciences
PACB
$619M
| – | – |
-1,574,379
| Closed | -$8.71M | – |
|
62
Precigen
PGEN
$2.64B
| – | – |
-213,033
| Closed | -$4.82M | – |
|
63
Perrigo
PRGO
$2.21B
| – | – |
-1,700
| Closed | -$210K | – |
|
64
Sonida Senior Living
SNDA
$1.72B
| – | – |
-39,820
| Closed | -$12.6M | – |
|
65
Vertex Pharmaceuticals
VRTX
$126B
| – | – |
-108,262
| Closed | -$8.21M | – |
|
66
Verastem
VSTM
$698M
| – | – |
-2,583
| Closed | -$386K | – |
|
67
Zoetis
ZTS
$31.1B
| – | – |
-465,900
| Closed | -$14.5M | – |
|
|
ARIA
68
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-1,264,009
| Closed | -$23.3M | – |
|
|
CTRX
69
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| – | – |
-508,100
| Closed | -$23.3M | – |
|
|
CBST
70
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| – | – |
-452,600
| Closed | -$28.8M | – |
|
71
DELISTED
ARTHROCARE CORP
ARTC
| – | – |
-342,759
| Closed | -$12.2M | – |
|
72
DELISTED
Repros Therapeutics Inc.
RPRX
| – | – |
-10,500
| Closed | -$281K | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q4 2013 Portfolio in Review
As of Q4 2013, Redmile Group held 72 positions worth $810M, up 22% from $664M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Redmile Group deployed $85.4M of net new capital in Q4 2013, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 378,669 shares worth $34.3M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was St Jude Medical, an estimated $25.8M trimmed.
- Redmile Group's largest Q4 2013 buy was Zimmer Biomet: 378,669 shares worth $34.3M.
- Redmile Group added most to Allergan Inc in Q4 2013, an estimated $18.8M increase.
- Redmile Group's biggest Q4 2013 reduction was St Jude Medical, cutting an estimated $25.8M.
- Redmile Group fully exited Amgen in Q4 2013, selling an estimated $38.7M.
- Redmile Group's ten largest holdings make up 37% of its $810M portfolio in Q4 2013.
- Redmile Group opened 23 new positions and closed 15 in Q4 2013.
- Redmile Group's portfolio value rose 22% quarter-over-quarter to $810M.
Based on Redmile Group's 13F filing for Q4 2013, filed 14 Feb 2014.